Meiji Pharma launches two Santen ophthalmic products in Indonesia
Category: #health  By Pankaj Singh  Date: 2019-08-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Meiji Pharma launches two Santen ophthalmic products in Indonesia

Reports confirm that Meiji Seika Pharma Co., Ltd. (Meiji), a Japanese company, has recently announced the launch of two products from Santen Pharmaceutical Co. (Santen) in Indonesia, which is based on a working business agreement that Meiji commenced in November of 2018 with Santen.

Sources close to the matter informed that on the basis of the working business agreement with Santen, these two products will be commercialized in Indonesia by affiliated subsidiary of Meiji, PT. Meiji Indonesian Pharmaceutical Industries (PT. Meiji). PT. Meiji has set up a new team for marketing specializing in ophthalmic treatments, and Santen will reinforce their overall marketing activities.

Apparently, Santen and PT. Meiji work mutually to expand their market share in Indonesia for ophthalmic products. Through the marketing of ophthalmic treatments in the country, Santen and Meiji are greatly contributing towards the health of the people across ASEAN countries.

Sources further mentioned that in 2018, Santen Inc., a global company focused entirely on ophthalmology, had unveiled the expansion of its R&D leadership team through addition of two new executives namely and Peter Sallstig, MD, MBA, appointed as Senior Vice President of Global Product Development and Reza M. Haque, MD, PhD, chosen as Senior Vice President of Global Research and Development Strategy.

Seemingly, Dr. Haque was to lead the global research and development strategy for all the fields of ophthalmology including retina, glaucoma, cornea, and external diseases. On the other hand, Dr. Sallstig was responsible for the execution, design, and strategy of clinical ophthalmology programs through all sessions of development, post-marketing, and regulatory submissions.

Head and Chief Scientific Officer of Global Research and Development, Naveed Shams, MD, PhD, had said at the time that bolstering the global research and development leadership team with Peter and Reza was vital for Santen as the company looked to advance its innovative ophthalmic pipeline.

                                                                   

Source Credits: https://finance.yahoo.com/news/meiji-seika-pharma-launch-two-010000836.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Flipkart launches Loyalty Program across 5,000 retail outlets in India
Flipkart launches Loyalty Program across 5,000 retail outlets in India
By Pankaj Singh

E-commerce giant Flipkart has recently launched SuperCoin Pay, a system of currency which its customers will have the right to use across tons of retail stores in the country. Flipkart is betting on its loyalty program...

Sirnaomics reveals dose administration of 1st patient in STP705 trial
Sirnaomics reveals dose administration of 1st patient in STP705 trial
By Pankaj Singh

Sirnaomics, Inc., a clinical-stage biopharmaceutical company, has recently announced the dose administration of the 1st patient in a Phase 2a clinical trial of STP705. STP705 is a lead drug candidate develop...

Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
By Pankaj Singh

The pharma giant Pfizer Inc. has reportedly declared that the U.S. Food and Drug Administration (US FDA) has approved the sNDA (supplemental New Drug Application) for XALKORI® (crizotinib) for the treatment of chil...